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Introduction: Antimicrobial resistant pathogens that cause healthcare-associated infections 
(HAI) pose serious challenges to healthcare Institutions. ESKAPE bacterial pathogens 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumanii, 
Pseudomonas aeruginosa, and Enterobacter spp.) are drug resistant HAI bacterial pathogens that 
pose the most threat globally and in Kazakhstan. Thus, there is an urgent need for discovery of new 
and efficacious drugs. Actinomycetes bacterial strains are the main producers of currently used 
antibiotics, including streptomycin, tetracycline, lincomycin, and others. Microorganisms that exist 
in extreme environment such as high salt or alkalinity known as extremophiles include 
Actinomycetes species. The goal of this study is discover novel antibiotics from Kazakhstan against 
ESKAPE pathogens from actinomycetes grown in extreme conditions by selecting active extracts 
for antibacterial activity. This will be followed by further analysis for chemical characterization and 
compound identification 
Methods: Soil from extreme environments of Kazakhstan was collected and cultured for 
isolation of pure cultures of Actinomycetes species. Pure strains of Actinomycetes were then 
cultured in modified Bennett's broth containing either high salt or high pH to mimic extreme 
environment in soil. Antimicrobial compound was extracted with butanol and tested for activity 
against S.aureus and E.coli. After this screening, disk diffusion assay was performed to assess the 
inhibitory activity of the extracts against hospital strains of ESKAPE pathogens. 
Results: A total number of 5936 strains were isolated from variants of modified Bennett's 
agar; from these, 2019 strains of extremophile actinomycetes were further isolated into pure culture 
(756 strains from Northern Kazakhstan and 1263 strains from Southern Kazakhstan). Of these, 415 
actinomycetes strains were chosen and analyzed based on their ability to show antibacterial 
inhibitory activities. Zones of inhibition for A. baumanii, S. aureus, and E. faecium were detected 
when these organisms were grown in the presence of some of these extracts. 
Conclusion: From screening a few hundred extremophile strains, we identified some 
interesting candidate extracts with putatative antibacterial activities against several Kazakhstan 
hospital strains of ESKAPE pathogens. Initial chemical characterization of the extracts was 
performed using HPLC and showed promising results. These extracts are being further investigated 
for their specific therapeutic potential as novel antimicrobial. 
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